Boston Scientific Corporation (BSX) : The consensus on Boston Scientific Corporation (BSX) based on 20 analyst recommendation on the company stock is 1.63, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 analyst believes that the stock is a Buy, which can produce decent returns in the future. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Boston Scientific Corporation (BSX) : 19 Wall Street analysts covering Boston Scientific Corporation (BSX) believe that the average level the stock could reach for the short term is $23.95. The maximum price target given is $28 and the minimum target for short term is around $20, hence the standard deviation is calculated at $2.27.
Boston Scientific Corporation (NYSE:BSX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.21 and $23.16 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.69. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.67, notching a gain of 1.59% for the day. The total traded volume was 12,576,748 . The stock had closed at $23.30 on the previous day.
Also, Guggenheim Securities initiates coverage on Boston Scientific Corporation (NYSE:BSX). According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 9, 2016. The company shares have rallied 33.52% from its 1 Year high price. On Jul 1, 2016, the shares registered one year high at $23.43 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $22.72 and the 200 Day Moving Average price is recorded at $19.64.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.